Literature DB >> 23290631

Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility.

Israr-Ul H Ansari1, Todd Allen, Andrew Berical, Peter G Stock, Burc Barin, Rob Striker.   

Abstract

Hepatitis C virus (HCV) replication is limited by cyclophilin inhibitors but it remains unclear how viral genetic variations influence susceptibility to cyclosporine (cyclosporine A, CsA), a cyclophilin inhibitor. In this study HCV from liver transplant patients was sequenced before and after CsA exposure. Phenotypic analysis of NS5A sequence was performed by using HCV sub genomic replicon to determine CsA susceptibility. The data indicates an atypical proline at position 328 in NS5A causes increases CsA sensitivity both in the context of genotype 1a and 1b residues. Point mutants mimicking other naturally occurring residues at this position also increased (Ala) or decreased (Arg) replicon sensitivity to CsA relative to the typical threonine (genotype 1a) or serine (genotype 1b) at this position. This work has implications for treatment of HCV by cyclophilin inhibitors. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23290631      PMCID: PMC3761804          DOI: 10.1016/j.virol.2012.11.018

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

1.  Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3.

Authors:  Harshna Patel; E Jenny Heathcote
Journal:  Gut       Date:  2010-10-21       Impact factor: 23.059

2.  NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.

Authors:  Sue Ma; Joanna E Boerner; ChoiLai TiongYip; Beat Weidmann; Neil S Ryder; Michael P Cooreman; Kai Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 3.  New HCV therapies on the horizon.

Authors:  J Vermehren; C Sarrazin
Journal:  Clin Microbiol Infect       Date:  2011-02       Impact factor: 8.067

4.  Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.

Authors:  Kaku Goto; Koichi Watashi; Daisuke Inoue; Makoto Hijikata; Kunitada Shimotohno
Journal:  Cancer Sci       Date:  2009-06-26       Impact factor: 6.716

5.  Viral sequence evolution in acute hepatitis C virus infection.

Authors:  Thomas Kuntzen; Joerg Timm; Andrew Berical; Lia L Lewis-Ximenez; Andrea Jones; Brian Nolan; Julian Schulze zur Wiesch; Bin Li; Arne Schneidewind; Arthur Y Kim; Raymond T Chung; Georg M Lauer; Todd M Allen
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

6.  Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.

Authors:  Dries Verdegem; Aurélie Badillo; Jean-Michel Wieruszeski; Isabelle Landrieu; Arnaud Leroy; Ralf Bartenschlager; François Penin; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

7.  Cyclophilin inhibitors as a novel HCV therapy.

Authors:  Hengli Tang
Journal:  Viruses       Date:  2010-08-05       Impact factor: 5.818

8.  Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics.

Authors:  Artur Kaul; Sarah Stauffer; Carola Berger; Thomas Pertel; Jennifer Schmitt; Stephanie Kallis; Margarita Zayas; Margarita Zayas Lopez; Volker Lohmann; Jeremy Luban; Ralf Bartenschlager
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

9.  The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

Authors:  Sam Hopkins; Michael Bobardt; Udayan Chatterji; Jose A Garcia-Rivera; Precious Lim; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

10.  Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein.

Authors:  Timothy L Tellinghuisen; Katie L Foss; Jason C Treadaway; Charles M Rice
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

View more
  6 in total

Review 1.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

2.  Metadata-driven comparative analysis tool for sequences (meta-CATS): an automated process for identifying significant sequence variations that correlate with virus attributes.

Authors:  B E Pickett; M Liu; E L Sadat; R B Squires; J M Noronha; S He; W Jen; S Zaremba; Z Gu; L Zhou; C N Larsen; I Bosch; L Gehrke; M McGee; E B Klem; R H Scheuermann
Journal:  Virology       Date:  2013-09-14       Impact factor: 3.616

Review 3.  Cyclophilins as modulators of viral replication.

Authors:  Stephen D Frausto; Emily Lee; Hengli Tang
Journal:  Viruses       Date:  2013-07-11       Impact factor: 5.048

Review 4.  Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses.

Authors:  Rob Striker; Andrew Mehle
Journal:  PLoS Pathog       Date:  2014-11-06       Impact factor: 6.823

5.  Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.

Authors:  Philippe A Gallay; Udayan Chatterji; Michael D Bobardt; Zhengyu Long; Shengli Zhang; Zhuang Su
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

6.  The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

Authors:  Philippe A Gallay; Michael D Bobardt; Udayan Chatterji; Daniel J Trepanier; Daren Ure; Cosme Ordonez; Robert Foster
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.